Related Experiment Video
Updated: Jun 11, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis?
Elmira Khabusheva1,2, Margaret A Goodell1,2
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Abstract:
In this issue, Waarts and colleagues developed an advanced ex vivo CRISPR screening platform to identify vulnerabilities in clonal hematopoiesis (CH). This unique system allowed the authors to identify a link between IDH2 and TET2 CH mutations, histone demethylases, and altered cytokine signaling, which enabled targeting by ruxolitinib leading to the elimination of CH clones, offering a possible path for preventing the development of malignancy. See related article by Waarts et al., p. 1860.
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells

